Using the TCGA dataset, BMX mutation had occurred in 2% of the samples that were tested (10967 samples from 32 studies); the majority of BMX mutations occurred in endometrial cancer with 7.18% (38 patients) mutations and 0.57% (3 patients) deep deletions. This evidence concerns the gene BMX and endometrial cancer.